21st week of 2020 patent applcation highlights part 26 |
Patent application number | Title | Published |
20200157144 | ANTIMICROBIAL PEPTIDOMIMETICS | 2020-05-21 |
20200157145 | NEUTRAL-CATIONIC PEPTOIDS AND USES THEREOF | 2020-05-21 |
20200157146 | CONTROLLED MODULATION OF AMINO ACID SIDE CHAIN LENGTH OF PEPTIDE ANTIGENS | 2020-05-21 |
20200157147 | POLYPEPTIDE DERIVED FROM CAP1 AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE INGREDIENT | 2020-05-21 |
20200157148 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS OF THE BLOOD, IN PARTICULAR CHRONIC LYMPHOID LEUKEMIA (CLL) | 2020-05-21 |
20200157149 | Cell Permeable Cyclic Peptide Scaffolds | 2020-05-21 |
20200157150 | ANTICANCER PEPTIDES | 2020-05-21 |
20200157151 | PEPTIDE COMPOUNDS, CONJUGATE COMPOUNDS AND USES THEREOF FOR TREATING INFLAMMATORY DISEASES | 2020-05-21 |
20200157152 | EXPRESSION OF KLEBSIELLA OXYTOCA POLYPEPTIDES INVOLVED IN LYSINE DECARBOXYLATION, AND METHODS AND APPLICATIONS THEREOF | 2020-05-21 |
20200157153 | SELF-ASSEMBLING PROTEIN SCAFFOLDS AND METHODS | 2020-05-21 |
20200157154 | MODIFIED Cry1Ca TOXINS USEFUL FOR CONTROL OF INSECT PESTS | 2020-05-21 |
20200157155 | PROTEIN EXPRESSION STRAINS | 2020-05-21 |
20200157156 | GRATELOUPIA CHIANGII-DERIVED LECTIN AND LECTIN GENE CODING FOR THE SAME | 2020-05-21 |
20200157157 | TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR | 2020-05-21 |
20200157158 | Modulation of Wnt5a to Treat Glaucoma | 2020-05-21 |
20200157159 | PEPTIDE COMPOUNDS AND COMPOSITIONS THEREOF | 2020-05-21 |
20200157160 | LYSIN-ANTIMICROBIAL PEPTIDE (AMP) POLYPEPTIDE CONSTRUCTS, LYSINS, ISOLATED POLYNUCLEOTIDES ENCODING SAME AND USES THEREOF | 2020-05-21 |
20200157161 | COMPOSITIONS FROM GASTROINTESTINAL TRACT MUCINS AND USES THEREOF | 2020-05-21 |
20200157162 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | 2020-05-21 |
20200157163 | PEPTIDE DERIVED FROM GPC3, PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF CANCER USING SAME, IMMUNITY INDUCER, AND METHOD FOR PRODUCING ANTIGEN-PRESENTING CELLS | 2020-05-21 |
20200157164 | RECOMBINANT HUMAN-BASIC FIBROBLAST GROWTH FACTOR (rh-bFGF) AND PHARMACEUTICAL COMPOSITION COMPRISING rh-bFGF | 2020-05-21 |
20200157165 | PEPTIDES HAVING OSTEOBLAST GROWTH-PROMOTING ACTIVITY AND USE THEREOF | 2020-05-21 |
20200157166 | METHODS OF PRODUCING AGGREGATE-FREE MONOMERIC DIPHTHERIA TOXIN FUSION PROTEINS AND THERAPEUTIC USES | 2020-05-21 |
20200157167 | USE OF LAMBDA INTERFERONS IN THE TREATMENT OF OBESITY-RELATED DISORDERS AND RELATED DISEASES | 2020-05-21 |
20200157168 | ACYLATED GLUCAGON ANALOGUES | 2020-05-21 |
20200157169 | ULTRA-LONG ACTING INSULIN-FC FUSION PROTEINS AND METHODS OF USE | 2020-05-21 |
20200157170 | ULTRA-LONG ACTING INSULIN-FC FUSION PROTEINS AND METHODS OF USE | 2020-05-21 |
20200157171 | ULTRA-LONG ACTING INSULIN-FC FUSION PROTEINS AND METHODS OF USE | 2020-05-21 |
20200157172 | NOVEL THERAPEUTIC ENZYME FUSION PROTEIN AND USE THEREOF | 2020-05-21 |
20200157173 | CHIMERIC ANTIGEN RECEPTOR, REGULATORY CELLS AND METHODS OF USE | 2020-05-21 |
20200157174 | PROTEINS BINDING NKG2D, CD16 AND ROR1 OR ROR2 | 2020-05-21 |
20200157175 | COMBINATIONS OF MHC CLASS IB MOLECULES AND PEPTIDES FOR TARGETED THERAPEUTIC IMMUNOMODULATION | 2020-05-21 |
20200157176 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST ESOPHAGEAL CANCER AND OTHER CANCERS | 2020-05-21 |
20200157177 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AND METHODS FOR GENERATING SCAFFOLDS FOR THE USE AGAINST PANCREATIC CANCER AND OTHER CANCERS | 2020-05-21 |
20200157178 | CHIMERIC ANTIGEN RECEPTORS SPECIFIC TO AVB6 INTEGRIN AND METHODS OF USE THEREOF TO TREAT CANCER | 2020-05-21 |
20200157179 | CD47 BLOCKADE THERAPY | 2020-05-21 |
20200157180 | FUSION PROTEIN CONTAINING TGF- RECEPTOR AND MEDICINAL USES THEREOF | 2020-05-21 |
20200157181 | METHOD FOR PREDICTING THE OUTCOME OF A TREATMENT WITH AFLIBERCEPT OF A PATIENT SUSPECTED TO SUFFER FROM A CANCER | 2020-05-21 |
20200157182 | TGF-BETA RECEPTOR TYPE II VARIANTS AND USES THEREOF | 2020-05-21 |
20200157183 | METHOD FOR PRODUCING MONOMERIC AND MULTIMERIC MOLECULES AND USES THEREOF | 2020-05-21 |
20200157184 | BIOSENSORS FOR MONITORING BIOMOLECULE LOCALIZATION AND TRAFFICKING IN CELLS | 2020-05-21 |
20200157185 | HUMAN COAGULATION FACTOR IX (FIX) FUSION PROTEIN, PREPARATION METHOD THEREFOR, AND USE THEREOF | 2020-05-21 |
20200157186 | TRUNCATED VWF | 2020-05-21 |
20200157187 | ANTIGEN-SPECIFIC REAGENTS SPECIFIC TO ACTIVE TGF-BETA, METHODS OF PRODUCING THE SAME, AND METHODS OF USE | 2020-05-21 |
20200157188 | SYNTHETIC HEME-CONTAINING MOLECULES AND THEIR USE | 2020-05-21 |
20200157189 | Method for selecting polypeptide producing cells | 2020-05-21 |
20200157190 | MONOVALENT AND DIVALENT BINDING PROTEINS | 2020-05-21 |
20200157191 | MVA-gH/gL-PC VACCINE DERIVED ANTIBODIES NEUTRALIZING HUMAN CYTOMEGALOVIRUS INFECTIVITY AND METHODS THEREOF | 2020-05-21 |
20200157192 | FC-FUSION PROTEIN DERIVATIVES WITH HIGH DUAL HIV ANTIVIRAL AND IMMUNOMODULATORY ACTIVITY | 2020-05-21 |
20200157193 | ANTI-STAPHYLOCOCCUS ANTIBODIES AND USES THEREOF | 2020-05-21 |
20200157194 | Human Antibodies to GREM1 | 2020-05-21 |
20200157195 | 14-3-3 Antagonists for the Prevention and Treatment of Arthritis | 2020-05-21 |
20200157196 | Treatment Of Autoimmune Disease By Modulating Annexin-1 (Lipocortin 1) | 2020-05-21 |
20200157197 | COMPOSITION AND METHODS FOR TREATING SNAKE ENVENOMATION | 2020-05-21 |
20200157198 | NAV1.9 TARGET POLYPEPTIDE, ANTIBODY AND ANTIBODY FRAGMENT COMBINED WITH SAME, AND RELATED PHARMACEUTICAL COMPOSITION | 2020-05-21 |
20200157199 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES AND DISORDERS | 2020-05-21 |
20200157200 | ANTI-C5 ANTIBODIES HAVING IMPROVED PHARMACOKINETICS | 2020-05-21 |
20200157201 | METHODS FOR TREATING OSTEOARTHRISTIS PAIN BY ADMINISTERING A NERVE GROWTH FACTOR ANTAGONIST AND COMPOSITIONS CONTAINING THE SAME | 2020-05-21 |
20200157202 | USE OF ANTI-FAMILY WITH SEQUENCE SIMILARITY 19, MEMBER A5 ANTIBODIES FOR THE TREATMENT OF GLAUCOMA | 2020-05-21 |
20200157203 | OPTIMIZED ANTI-TL1A ANTIBODIES | 2020-05-21 |
20200157204 | Antibodies of the Class IGG4 | 2020-05-21 |
20200157205 | METHODS AND COMPOSITIONS FOR DELIVERING MRNA CODED ANTIBODIES | 2020-05-21 |
20200157206 | BIOPHARMACEUTICAL COMPOSITIONS AND METHODS FOR PEDIATRIC PATIENTS | 2020-05-21 |
20200157207 | ANTI-IL-22R ANTIBODIES | 2020-05-21 |
20200157208 | COMBINATION OF AN ANTIBODY THAT BINDS TO THE P19 SUBUNIT OF HUMAN IL-23 AND A HYALURONIDASE ENZYME | 2020-05-21 |
20200157209 | Safe and Effective Method of Treating Psoriasis with Anti-IL-23 Specific Antibody | 2020-05-21 |
20200157210 | FUSION PROTEIN | 2020-05-21 |
20200157211 | ANTI-BRIL ANTIBODY AND METHOD OF STABILIZING BRIL FUSION PROTEIN USING SAID ANTIBODY | 2020-05-21 |
20200157212 | ANTI-ROBO2 ANTIBODIES, COMPOSITIONS, METHODS AND USES THEREOF | 2020-05-21 |
20200157213 | MULTI-SPECIFIC ANTIBODIES AND METHODS OF MAKING AND USING THEREOF | 2020-05-21 |
20200157214 | ANTI-CEACAM6 ANTIBODIES AND USES THEREOF | 2020-05-21 |
20200157215 | ANTIBODY MOLECULES WHICH BIND CD22 | 2020-05-21 |
20200157216 | T CELL RECRUITING POLYPEPTIDES CAPABLE OF BINDING CD123 AND TCR ALPHA/BETA | 2020-05-21 |
20200157217 | ANTI-CD3 ANTIBODIES AND METHODS OF MAKING AND USING THEREOF | 2020-05-21 |
20200157218 | BISPECIFIC ANTIBODIES TO ROR1 AND CD3 | 2020-05-21 |
20200157219 | ANTI-PD-1 ANTIBODIES AND METHODS OF MAKING AND USING THEREOF | 2020-05-21 |
20200157220 | CTLA4 BINDERS | 2020-05-21 |
20200157221 | ONCOLYTIC VIRAL DELIVERY OF THERAPEUTIC POLYPEPTIDES | 2020-05-21 |
20200157222 | ANTI-PD-L1 ANTIBODIES AND USES THEREOF | 2020-05-21 |
20200157223 | BISPECIFIC RECOMBINANT PROTEIN AND USE THEREOF | 2020-05-21 |
20200157224 | MULTI-SPECIFIC ANTIBODIES AND METHODS OF MAKING AND USING THEREOF | 2020-05-21 |
20200157225 | INHIBITOR OF SUV39H1 HISTONE METHYLTRANSFERASE FOR USE IN CANCER COMBINATION THERAPY | 2020-05-21 |
20200157226 | PROTEINS BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN | 2020-05-21 |
20200157227 | PROTEINS BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN | 2020-05-21 |
20200157228 | METHODS OF TREATMENT USING ANTI-CD123 IMMUNOCONJUGATES | 2020-05-21 |
20200157229 | METHOD FOR TREATING ALLERGIC CONTACT DERMATITIS | 2020-05-21 |
20200157230 | DAC HYP COMPOSITIONS AND METHODS | 2020-05-21 |
20200157231 | DIAGNOSIS AND TREATMENT OF CANCER USING ANTI-LGR7 ANTIBODY | 2020-05-21 |
20200157232 | ANTI-BCMA HEAVY CHAIN-ONLY ANTIBODIES | 2020-05-21 |
20200157233 | ANTAGONISTIC CD40 MONOCLONAL ANTIBODIES AND USES THEREOF | 2020-05-21 |
20200157234 | ANTI-CD137 ANTIBODIES | 2020-05-21 |
20200157235 | METHODS FOR TREATING PROGRESSIVE MULTIPLE SCLEROSIS | 2020-05-21 |
20200157236 | Anti-ALK Antibodies and Methods for Use Thereof | 2020-05-21 |
20200157237 | LYMPHOCYTE ANTIGEN CD5LIKE (CD5L) MONOMER, HOMODIMER, AND INTERLEUKIN 12B (P40) HETERODIMER ANTAGONISTS AND METHODS OF USE THEREOF | 2020-05-21 |
20200157238 | PERTUZUMAB VARIANTS AND EVALUATION THEREOF | 2020-05-21 |
20200157239 | REMOVAL OF TARGET CELLS BY CIRCULATING VIRUS-SPECIFIC CYTOTOXIC T-CELLS USING MHC CLASS I COMPRISING COMPLEXES | 2020-05-21 |
20200157240 | PEPTIDOMIMETIC COMPOUNDS AND ANTIBODY-DRUG CONJUGATES THEREOF | 2020-05-21 |
20200157241 | ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III CHIMERIC ANTIGEN RECEPTORS AND USE OF SAME FOR THE TREATMENT OF CANCER | 2020-05-21 |
20200157242 | IMMUNOGLOBULIN COMPOSITIONS AND PROCESS FOR OBTAINING THE SAME | 2020-05-21 |
20200157243 | PHARMACEUTICAL COMPOSITION FOR USE IN PREVENTION AND/OR TREATMENT OF DISEASE THAT DEVELOPS OR PROGRESSES AS A RESULT OF DECREASE OR LOSS OF ACTIVITY OF BLOOD COAGULATION FACTOR VIII AND/OR ACTIVATED BLOOD COAGULATION FACTOR VIII | 2020-05-21 |